NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PHAS shares have increased by 31.3% and is now trading at $4.11.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.10. The business earned $0.32 million during the quarter, compared to the consensus estimate of $0.38 million. PhaseBio Pharmaceuticals had a negative net margin of 2,310.60% and a negative return on equity of 70.50%.
View PhaseBio Pharmaceuticals' earnings history.

6 brokerages have issued 1-year price targets for PhaseBio Pharmaceuticals' shares. Their forecasts range from $4.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 216.3% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals.

News coverage about PHAS stock has trended somewhat negative on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. PhaseBio Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.
View the latest news about PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 3,330,000 shares, an increase of 6.4% from the June 30th total of 3,130,000 shares. Based on an average daily trading volume, of 785,900 shares, the short-interest ratio is currently 4.2 days. Currently, 22.5% of the company's shares are short sold.
View PhaseBio Pharmaceuticals' Current Options Chain.

Some companies that are related to PhaseBio Pharmaceuticals include Corbus Pharmaceuticals (CRBP), Tocagen (TOCA), AC Immune (ACIU), BioSpecifics Technologies (BSTC), Clovis Oncology (CLVS), Syros Pharmaceuticals (SYRS), Urogen Pharma (URGN), Crinetics Pharmaceuticals (CRNX), DURECT (DRRX), XBiotech (XBIT), Protagonist Therapeutics (PTGX), Ocular Therapeutix (OCUL), BioDelivery Sciences International (BDSI), Puma Biotechnology (PBYI) and Catalyst Pharmaceuticals (CPRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

PhaseBio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (0.10%), Leap Investments LP (0.05%) and Wedbush Securities Inc. (0.04%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras.
View institutional ownership trends for PhaseBio Pharmaceuticals.

PHAS stock was purchased by a variety of institutional investors in the last quarter, including Leap Investments LP, Wedbush Securities Inc., and First Trust Advisors LP. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson, and Venture Advisors Iii Hatteras.
View insider buying and selling activity for PhaseBio Pharmaceuticals.

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PHAS stock can currently be purchased for approximately $4.11.

PhaseBio Pharmaceuticals has a market capitalization of $118.29 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]